drugset / Trial / NCT01757392
Candin Safety & Efficacy Study for the Treatment of Warts
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
Timeline
- Start
- 2012-09
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candin | Other / unclassified | 0.3 ml | Other |